Besides the acute phase gastrointestinal effects which may lead to up to 10% of people discontinuing the drugs, there are other potential GI side effects of obstruction, excessive loss of muscle mass, and potentially association with some eye disease adverse events
The chronic morbidity burden of COVID-19 extends much wider, with up to 10% of individuals across a spectrum of initial disease severity estimated to suffer from long COVID, a durable multisystemic condition with multiple adverse outcomes, such as, myalgia, fatigue, and neurocognitive dysfunction [7]
Are AOD-9604 and MOTS-c FDA-approved
Understanding these mechanisms highlights the need to diagnose and treat B12 deficiency
ATGL, HSL, MGL, lipid-droplet proteins, coactivators, inhibitory proteins, intracellular localization, and substrate accessibility all influence the measured rate of lipid mobilization